Quest Diagnostics Inc. closed 8.28% below its 52-week high of $178.87, which the company reached on March 10th.

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

With a market cap of $18.5 billion, Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic testing and ...

Quest Diagnostics is Thursday's IBD Stock Of The Day ... driven by strong core performance and contributions from acquisitions. Quest Diagnostics Incorporated ( NYSE:DGX ) will increase its ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

UBS Group lifted their price objective on shares of Quest Diagnostics from $166.00 to $170.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Finally ...

Despite Quest Diagnostics’ strong performance, analysts remain cautiously optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from the 16 analysts covering the ...

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine ...

stock has rallied 25.2% compared with the industry’s 2.9% growth and the S&P 500 composite’s 10.6% rise. The renowned provider of diagnostic information services has a market capitalization of $18.38 ...